Normas de Prevención, Diagnóstico Temprano y Tratamiento de Cáncer Cérvico-Uterino

Objectives

Establish nationwide standards for prevention, early detection, diagnosis, treatment and follow-up of cervical cancer in the Dominican Republic, supporting health-sector reform, equitable access to quality services, and progressive reductions in avoidable morbidity and mortality among women.[1][2][3]The standards apply across public, private, mixed and decentralised health services, particularly establishments providing reproductive-health care.[1][3]

• Harmonise clinical, therapeutic and prevention criteria across all levels of care, including use of the Bethesda System for cytology reporting and improved quality of Papanicolaou smear collection.[2][4]
• Prioritise promotion, vaccination where feasible, and screening for women aged 35 to 64, women who have never had a Pap test, and other women at higher risk while continuing to provide services on request.[5][6]
• Identify premalignant and malignant lesions through cervical cytology, human papillomavirus DNA testing where facilities permit, visual inspection, colposcopy, biopsy and histopathology.[7][8]
• Provide early management of premalignant lesions and refer suspected microinvasive or invasive cancer to hospitals with gynaecological oncology services.[9][10][11]
• Strengthen health information, education and communication, particularly for women, to support prevention of cervical lesions and timely uptake of detection services.[12]
• Support institutional quality, sustainable service management, documentation, supervision and improved statistical reporting for cervical-health services.[1][2]

Implementation

Implement the standards as a mandatory national framework through public, private and mixed-sector reproductive-health establishments, combining community promotion, primary-care screening, referral pathways, specialised cervical pathology services and clinical follow-up.[3][6][13]Governance rests within the legal and policy responsibilities of the State Secretariat of Public Health and Social Assistance, with designated national, provincial, area and regional health authorities responsible for implementation oversight.[14][3]

• Coordinate implementation through the General Directorate for Maternal and Adolescent Health, the National Standards Directorate and the cervical cancer programme, working with Provincial, Area and Regional Health Directorates.[3]
• Engage the Executive Commission for Health Sector Reform, the United Nations Population Fund, the Pan American Health Organization, professional societies, academic institutions and national health-sector bodies that contributed to revision of the standards.[15][16]
• Deliver promotion through health centres, home visits, health councils, community organisations, workplaces, trade unions, non-governmental organisations, publications, counselling, talks, brochures, posters and mass media.[12][6]
• Use nurses, doctors, social workers, family-health technicians, communicators and other trained personnel to undertake individual and collective education and support programme delivery.[12]
• Offer human papillomavirus vaccination to people aged 9 to 26 where vaccine supply is available, using a three-dose schedule at the initial visit, two months and six months.[6]The standards note that high vaccine cost has limited expansion in developing countries.[6]
• Provide Pap testing at all levels of care, particularly through primary care, with liquid-based cytology where available; provide or refer for human papillomavirus DNA hybrid-capture testing in appropriately equipped centres.[7]
• Require trained clinical, nursing or other appropriately trained personnel to explain sampling, complete forms and registers, label and immediately fix specimens, obtain cells from the squamocolumnar junction, and send samples to laboratories within five days.[17][4]
• Refer abnormal cytology results to cervical pathology clinics with cytology results and referral documentation, and use colposcopy, biopsy and histopathology to determine management.[8][17]Referral and counter-referral forms record clinical information, investigations, treatment and recommendations between referring and receiving services.[18][19]
• Locate cervical pathology clinics in third- or fourth-level hospitals or oncology centres, with capacity for colposcopic diagnosis and conservative treatment, including biopsy, endocervical sampling, conisation and electrosurgery.[9]Staff second- and third-level services with gynaecologists or oncologists trained in cervical pathology and colposcopy.[13][20]
• Manage low-grade and high-grade lesions according to lesion characteristics, using excisional approaches such as loop diathermy or surgical conisation, and destructive methods such as electrocoagulation or laser where appropriate.[21][22]Refer suspected invasive disease to specialised gynaecological oncology care.[10][11]
• Adapt care during pregnancy by collecting cytology during antenatal care, using colposcopy for abnormal findings, limiting biopsy to suspected invasive cancer, avoiding endocervical curettage, and reassessing lesions after delivery.[10]
• Maintain clinical documentation through cytology and colposcopy reports, registration books, appointment records, biopsy reports, referral forms and management flowcharts.[4][23][24]
• Supervise application of health legislation and standards, assess promotion activities through analysis of results, and use documentation and statistical reporting to support quality oversight.[14][6][2]The supplied material does not specify a comprehensive programme-level indicator set, reporting schedule, budget, resource-allocation formula or quantified financing plan.[2][3][25]

Monitoring & Evaluation

The standards establish a largely clinical and administrative monitoring framework for cervical cancer prevention, screening, diagnosis, treatment and referral. It combines institutional supervision, standardised diagnostic classification, patient documentation, clinical follow-up and statistical reporting, but does not set out a comprehensive programme-level indicator framework, reporting timetable or evaluation methodology.[2][3][4][13]

• Assign supervision, evaluation and surveillance responsibilities to the General Directorate for Maternal and Adolescent Health, the National Standards Directorate and the cervical cancer programme, coordinated with Provincial, Area and Regional Health Directorates.[3]
• Require health authorities to oversee compliance with health legislation and regulations, while health-establishment management is responsible for safe and correct performance by personnel.[14]
• Strengthen documentation for reports and statistics, establish adequate supervision, and improve statistical reporting as explicit objectives of the standards.[2]
• Standardise cytology reporting through the Bethesda System, including specimen adequacy, benign cellular changes, epithelial abnormalities and glandular abnormalities.[2][4]
• Improve quality assurance for Pap smear collection through specified sampling, labelling, fixation, form-completion and record-keeping procedures.[2][17]
• Record sampling, appointments, referrals, results and follow-up actions in registration books, clinical forms and patient appointment cards.[17][4][13]
• Use referral and counter-referral forms to document clinical information, cytology, colposcopy, biopsy, treatment, recommendations, service locations, dates and clinicians’ signatures.[18][19]
• Classify colposcopic findings as normal, abnormal, miscellaneous or inconclusive, and record diagnostic impressions including inflammation, human papillomavirus infection, low-grade and high-grade lesions, and invasive cancer.[23]
• Submit biopsy specimens with the relevant report sheet to the pathology laboratory within five days, supported by a clinical form and lesion drawing.[23]
• Apply clinical follow-up intervals for detected lesions, including six-monthly cytology and colposcopy for low-grade lesions and six-monthly monitoring for two years after treatment of high-grade disease.[22][10]
• Monitor low-grade and high-grade lesions during pregnancy through colposcopy and cytology every four months, with reassessment six weeks after delivery.[10]
• Assess the impact of health-promotion activities through analysis of results by participating institutions.[6]

Evidence cited in the standards includes a hospital tumour-registry estimate that cervical cancer represented 22.4% of recorded cancer cases in the Dominican Republic in 2004.[5]The supplied material does not define national targets, denominators, performance thresholds, reporting frequency, data flows, audit arrangements, evaluation tools or public accountability reports.[2][3][6][24][25]

Costing & Financing

The supplied material contains very limited financing information. It identifies external support for publication and recognises the affordability challenge of human papillomavirus vaccination, while providing no implementation budget, quantified resource plan, allocation formula, funding-gap estimate or wider economic analysis for the national standards.[15][6][25]

• Record sponsorship for printing of the 2007 publication from the United Nations Population Fund; the support is noted without a financial amount or funding conditions.[15]
• Identify the high cost of human papillomavirus vaccination as a constraint on expansion in developing countries, and limit recommendation of vaccination to units able to obtain the vaccine.[6]
• Characterise loop diathermy as the treatment method with the best cost-benefit ratio for high-grade cervical lesions, without supplying a cost, comparator value or economic evaluation method.[22]
• Identify material resource requirements for cytology, including a speculum, spatula, cytobrush or endocervical brush, slides, fixative and documentation materials, without costing these inputs.[17]
• Identify diagnostic and treatment capacity requirements including biopsy, endocervical brushing, colposcopy, conisation and electrosurgery, without specifying associated capital, workforce or operating costs.[9]
• Require cervical pathology clinics in third- or fourth-level hospitals or oncology centres to provide colposcopic diagnosis and conservative treatment, but do not specify financing for these services.[9]

No budget, expenditure amount, financing source beyond publication sponsorship, resource-mobilisation mechanism, donor commitment, funding gap, unit cost, cost-effectiveness threshold or economic assumption is specified for delivery of screening, vaccination, diagnostic, treatment, referral or monitoring activities.[2][14][3][6][10][25]